Validation Of the Tau Heterogeneity Evaluation in Alzheimer's Disease (THETA) Score Using Longitudinal and Histopathology Data

Jan 1, 2024·

Robel K. Gebre

et al.

· 0 min read

Abstract

We validated the THETA score using longitudinal PET data and histopathology, demonstrating its association with disease progression and neuropathological staging.

Type

Conference paper

Publication

Alzheimer’s & Dementia

Last updated on Apr 6, 2026

← Identifying transition points in AD biomarkers using machine learning: A supplement to the reliable worsening method Jan 1, 2024

NODDI May Be More Sensitive to Neurodegenerative Changes Than Structural MRI Dec 1, 2023 →

No results found

Validation Of the Tau Heterogeneity Evaluation in Alzheimer's Disease (THETA) Score Using Longitudinal and Histopathology Data